



Three-dimensional Organoids as preclinical models





Preclinical models





An **ORGANOID** is defined as a cellular structure containing multiple organ-specific cell types, capable of recapitulating some specific function of the organ, and spatially organized similarly to an organ.


ORGANOIDS can be derived from pluripotent stem cells or adult stem cells.



optic vesicle-containing
brain organoids




Heart organoid



Kidney organoid


Mainstream Human Organoid Models



Modeling Development and Disease with Organoids

Cell

Hans Clevers^{1,*}




Schematic of the Various Regions of the Body that Can Be Cultured as aSC-Derived Organoids

Modeling Development and Disease with Organoids


Cell

Hans Clevers^{1,*}




Schematic of the Various Organoids that Can Be Grown from PSCs and the Developmental Signals that Are Employed


Organoids - Preclinical models of human disease



Two-Dimensional
Cell Cultures



Three-Dimensional Organoids



Animal Models

	Two-Dimensional Cell Cultures	Three-Dimensional Organoids	Animal Models
Physiologic representation	Limited	Semiphiologic	Physiologic
Vascularization and immune system	No	No	Yes
High-throughput screening	Yes	Yes	No
Manipulability	Excellent	Good, but may have experimental variability	Limited
Biobanking	Yes	Yes	Yes, but only at the cellular level
Genome editing	Yes	Yes	Yes, but may require generation of embryonic stem cells
Modeling organogenesis	Poor	Suitable for study of cell-cell communication, morphogenesis; reduced complexity	Yes, but often confounded by complex tissue environment
Modeling human development and disease	Poor owing to over-simplified nonphysiologic conditions	Yes	Yes

History of organoid methodologies

REVIEW

Organogenesis in a dish: Modeling development and disease using organoid technologies

Madeline A. Lancaster¹, Juergen A. Knoblich^{1,*}

* See all authors and affiliations


Science 18 Jul 2014;
Vol. 345, Issue 6194, 1247125
DOI: 10.1126/science.1247125




Yoshiki Sasai



J.C. Clevers



Citations to the Search Term "Organoids" in PubMed



[nature](#) > [nature methods](#) > [editorials](#) > [article](#)

MENU ▾

nature|methods


Editorial | [Published: 03 January 2018](#)

Method of the Year 2017: Organoids

Nature Methods **15**, 1 (2018) | [Download Citation](#) ↓


The ability to prod stem cells into three-dimensional tissue models makes for a powerful way to study human biology. But these exciting tools are still works in progress.

Intestinal organoid culture method




- Lgr5 crypt stem cells divide constantly;
- Stem cells numbers remain fixed because stem cells compete ‘neutrally’ for niche space;
- Daughters of the intestinal stem cells, the Paneth cells, serve as crypt niche cells by providing Wnt, Notch and EGF signals.


Intestinal organoid culture method




1. Intestinal biopsies



2. Crypt Isolation




3. Crypt Culture




- 1) Wash
2) Fungizone + Normocin + Gentamicin
3) EDTA incubation
4) Shake vigorously

Stem Organoid Medium:

R-spondin
WNT3a
Noggin
+ 12 reagents



Wnt Signaling




The Wnt/b-Catenin Signaling Pathway and Its Regulatory Loops.

Table 1. Frequently used growth media constituents, their working mechanisms and effects, as well as applications.


Growth medium constituents	Working mechanism in ISCs	Effect on ISCs and application
WNT3a ^a	Activates canonical WNT signaling (Clevers & Nusse, 2012)	Stimulates crypt cells proliferation and maintains the stem cell state (Clevers & Nusse, 2012; Farin <i>et al.</i> , 2012; Krausova & Korinek, 2014)
R-spondin 1 ^a	Augments WNT/ β -catenin signaling (de Lau <i>et al.</i> , 2014)	Stimulates crypt cell proliferation and maintains stem cell state (Farin <i>et al.</i> , 2012; Krausova & Korinek, 2014; de Lau <i>et al.</i> , 2014)
CHIR99021	Stimulates canonical WNT signaling (Yin <i>et al.</i> , 2014)	Stimulates stem cell proliferation and can be used in combination with VPA, when growing single mouse ISCs in absence of Paneth cells (Yin <i>et al.</i> , 2014)
Valproic acid	Inhibits histone deacetylase and activates Notch signaling (Yin <i>et al.</i> , 2014)	Maintains proliferative crypts and blocks secretory differentiation (Sato <i>et al.</i> , 2011b). Can be used in combination with CHIR99021 when growing single mouse ISCs in absence of Paneth cells (Yin <i>et al.</i> , 2014)
Noggin ^a	Inhibits BMP signaling (Haramis <i>et al.</i> , 2004)	Stimulates crypt formation (Haramis <i>et al.</i> , 2004)
Jagged-1	Activates Notch signaling (Sato <i>et al.</i> , 2009)	Maintains the stem cell state, and promotes proliferation, while blocking secretory differentiation, thereby maintaining proliferative crypts (Stanger <i>et al.</i> , 2005; Van Dussen <i>et al.</i> , 2012) Used in the early phase of single-cell cultures in absence of Notch signaling from adjacent supportive cells (Sato <i>et al.</i> , 2009; Grabinger <i>et al.</i> , 2014)
EGF ^a	Activates RAS/RAF/MEK/ERK signaling pathway (Suzuki <i>et al.</i> , 2010; Date & Sato, 2015)	Stimulates stem cell migration, proliferation, and inhibits apoptosis (Frey <i>et al.</i> , 2004; Suzuki <i>et al.</i> , 2010)
PGE ₂	Enhances canonical WNT signaling (Buchanan & DuBois, 2006)	Prevents anoikis as well as promotes stem cell survival and proliferation, thereby improving culture efficiency. Stimulates spheroid morphology (Cohn <i>et al.</i> , 1997; Joseph <i>et al.</i> , 2005)
Nicotinamide	Inhibits the activity of sirtuins (Denu, 2005)	Improves ISC maintenance when cultured > 1 week (Sato <i>et al.</i> , 2011a). Often used for long-term human intestinal organoid cultures (Sato <i>et al.</i> , 2011a), but can be omitted (Fujii <i>et al.</i> , 2015)
Gastrin-17	Not decisively concluded	Marginally increases culture efficiency (Sato <i>et al.</i> , 2011a)
A83-01 or SB431542 ^a	Inhibits TGF- β signaling (Sato <i>et al.</i> , 2011a)	Inhibits differentiation and allows human intestinal stem cell cultures to be sustained in the long term (Sato <i>et al.</i> , 2011a)
SB202190 ^a	Inhibits P38 MAPK (Sato <i>et al.</i> , 2011a)	Inhibits secretory differentiation, increases plating efficiency, and decreases degradation of the EGF receptor (Frey <i>et al.</i> , 2006; Sato <i>et al.</i> , 2011a; Date & Sato, 2015). Allows human intestinal stem cell cultures to be sustained in the long term (Sato <i>et al.</i> , 2011a)
Y-27632 or thiazovivin	Inhibition of caspase-3 (Wu <i>et al.</i> , 2015)	Prevents anoikis after single-cell dissociation (Watanabe <i>et al.</i> , 2007). Used in the early phase of single-cell cultures
IL-22	JAK/STAT signaling (Lindemans <i>et al.</i> , 2015)	ISC proliferation and organoid growth. Can potentially further increase ISC expansion and make EGF redundant (Lindemans <i>et al.</i> , 2015)

^aMandatory growth medium components for long-term culturing human intestinal stem cells as organoids.

Intestinal organoid culture method



Applications of organoid technology



Applications of organoid technology




Liver stem cell transplantation
Organoid culturing technique

Clevers Lab | NYNUS 30

<https://www.hubrecht.eu/research-groups/clevers-group/>



Applications of organoid technology




Potential Use of Human Stem Cell-Derived Intestinal Organoids to Study Inflammatory Bowel Diseases

Isabella Dotti, PhD, and Azucena Salas, PhD


Inflammatory Bowel Diseases





A. Genetic and epigenetic alterations



B. Epithelium-microbiota interactions



C. Epithelium-LP interactions



Lamina propria (LP)


Epithelial organoid cultures from patients with Inflammatory Bowel Diseases

Inflammatory bowel disease

ORIGINAL ARTICLE

Alterations in the epithelial stem cell compartment could contribute to permanent changes in the mucosa of patients with ulcerative colitis

Isabella Dotti,¹ Rut Mora-Buch,¹ Elena Ferrer-Picón,¹ Núria Planell,^{1,2} Peter Jung,^{3,4} M Carme Masamunt,¹ Raquel Franco Leal,^{1,5} Javier Martín de Carpi,⁶ Josep Llach,⁷ Ingrid Ordás,¹ Eduard Batlle,^{3,8} Julián Panés,¹ Azucena Salas¹





Epithelial organoid cultures from patients with Inflammatory Bowel Diseases

Inflammatory bowel disease

ORIGINAL ARTICLE

Alterations in the epithelial stem cell compartment could contribute to permanent changes in the mucosa of patients with ulcerative colitis

Isabella Dotti,¹ Rut Mora-Buch,¹ Elena Ferrer-Picón,¹ Núria Planell,^{1,2} Peter Jung,^{3,4} M Carme Masamunt,¹ Raquel Franco Leal,^{1,5} Javier Martín de Carpi,⁶ Josep Llach,⁷ Ingrid Ordás,¹ Eduard Batlle,^{3,8} Julián Panés,¹ Azucena Salas¹



- A specific expression signature characterizes EpOCs and d-EpOCs from patients with UC compared with non-IBD controls (antimicrobial defense, secretory and absorptive functions);

- Whole biopsies and organoid cultures from patients with UC show common expression features (>66%);

Epithelial organoid cultures from patients with IBDs



Gastroenterology 2018;154:585–598

BASIC AND TRANSLATIONAL—ALIMENTARY TRACT

DNA Methylation and Transcription Patterns in Intestinal Epithelial Cells From Pediatric Patients With Inflammatory Bowel Diseases Differentiate Disease Subtypes and Associate With Outcome



Kate Joanne Howell,^{1,3,*} Judith Kraiczy,^{1,*} Komal M. Nayak,¹ Marco Gasparetto,^{1,2} Alexander Ross,^{1,4} Claire Lee,^{1,2} Tim N. Mak,¹ Bon-Kyoung Koo,⁴ Nitin Kumar,⁵ Trevor Lawley,⁵ Anupam Sinha,⁶ Philip Rosenstiel,⁶ Robert Heuschkel,² Oliver Stegle,^{3,§} and Matthias Zilbauer^{1,2,4,§}



TI = Terminal ileum
AC = Ascending colon
SC = Sigmoid colon

Epithelial organoid cultures from patients with IBDs

Gastroenterology 2018;154:585–598


BASIC AND TRANSLATIONAL—ALIMENTARY TRACT

DNA Methylation and Transcription Patterns in Intestinal Epithelial Cells From Pediatric Patients With Inflammatory Bowel Diseases Differentiate Disease Subtypes and Associate With Outcome





Kate Joanne Howell,^{1,3,*} Judith Kraiczy,^{1,*} Komal M. Nayak,¹ Marco Gasparetto,^{1,2} Alexander Ross,^{1,4} Claire Lee,^{1,2} Tim N. Mak,¹ Bon-Kyoung Koo,⁴ Nitin Kumar,⁵ Trevor Lawley,⁵ Anupam Sinha,⁶ Philip Rosenstiel,⁶ Robert Heuschkel,² Oliver Stegle,^{3,§} and Matthias Zilbauer^{1,2,4,§}

- Disease associated epigenetic alterations in the intestinal epithelium are stable over time and are at least in part retained in ex-vivo organoid cultures;








Gut segment ● AC ▲ SC ■ TI
Diagnosis ● CD ● Control ● UC

TI = Terminal ileum
AC = Ascending colon
SC = Sigmoid colon







Organoids to study the interactions of the epithelium with the environment in mucosal injury

TNF α



Organoids to study the interactions of the epithelium with the environment in mucosal injury and wound repair

IFN- γ





Intestinal organoid cocultures with microbes

Intestinal organoid cocultures with microbes


Jens Puschhof, Cayetano Pleguezuelos-Manzano, Adriana Martinez-Silgado, Ninouk Akkerman, Aurelia Saftien, Charelle Boot, Amy de Waal, Joep Beumer, Devanjali Dutta, Inha Heo & Hans Clevers

Nature Protocols (2021) | [Cite this article](#)




Co-culture with intestinal epithelial organoids

Lymphocytes can be expanded with epithelial organoids and efficiently maintained within and outside a 3-D system for a period of 2 weeks





IL-2/-7/-15 enhances expansion of $\alpha\beta$ T and $\gamma\delta$ T of intraepithelial lymphocytes





Motility analysis of intraepithelial lymphocytes in the co-culture system

Culturing human intestinal stem cells for regenerative applications in the treatment of inflammatory bowel disease

Fredrik EO Holmberg¹, Jakob B Seidelin¹, Xiaolei Yin^{2,3,4,5,6}, Benjamin E Mead^{2,3,4,5,6,7}, Zhixiang Tong^{2,3,4,5}, Yuan Li¹, Jeffrey M Karp^{2,3,4,5,6,7,*} & Ole H Nielsen^{1,*} 




CRISPR/Cas9-Mediated Genome Editing in Adult Stem Cells



Functional Repair of CFTR by CRISPR/Cas9 in Intestinal Stem Cell Organoids of Cystic Fibrosis Patients




Gerald Schwank,^{1,2,7} Bon-Kyoung Koo,^{1,2,7,8} Valentina Sasselli,^{1,2} Johanna F. Dekkers,^{3,4} Inha Heo,^{1,2} Turan Demircan,¹ Nobuo Sasaki,^{1,2} Sander Boymans,¹ Edwin Cuppen,^{1,6} Cornelis K. van der Ent,³ Edward E.S. Nieuwenhuis,⁵ Jeffrey M. Beekman,^{5,6} and Hans Clevers^{1,2,*}




Forskolin induces swelling of organoids from healthy subjects, but the swelling is absent in organoids from patients with CF.

Drug response in patient-derived organoids


High-throughput drug screening



● Potential lead



Patient-derived organoids in personalized medicine




Barfeld and Clevers, J Mol Med, 2017

CFTR ASSAY

Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis

wild-type CFTR


F508del/F508del



Dekkers et al., Nature Med, 2013

Dekkers et al., Sci Trans Med, 2016


Drug response in patient-derived organoids





Trends in Biotechnology, April 2018, Vol. 36, No. 4

In this approach, the procedure begins with sequencing tumor biopsies or dissected samples by using the next-generation sequencing method and continues with culturing patient-derived tumor organoids, which will be histologically and pathologically compared with the primary tumors before they are subjected to drug screening. In parallel, part of the derived organoids will be preserved as a biobank. To determine effective therapeutic strategies, based on the sequencing results and gene-drug association links, high-throughput drug screening of candidate drugs that include standard chemotherapy and targeted therapy agents can be performed in a replicative process.



Cell Viability Assay: CellTiter-Glo® 3D



Cell Viability Assay: MTT Reagent



Cell Viability Assay: Thymidine incorporation, BrdU and EdU




Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer

Lee et al., 2018, Cell 173, 515–528

CellPress

22 patient-derived bladder cancer organoid lines:

- histopathological and molecular concordance with their corresponding parental tumors;
- display changes in their mutational profiles during culture and xenografting consistent with clonal evolution.





Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer


Lee et al., 2018, Cell 173, 515–528

CellPress


PRESENCE OF ACTIVATING MUTATIONS IN FGFR3



↓
Proliferation




A




Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer

Lee et al., 2018, Cell 173, 515–528


Effects of 40 compounds (standard therapies and agents being tested in clinical trials)



C




DRUG RESPONSE IN PATIENTS WITH RECURRENT BLADDER CANCER






These results suggest that drug responses in the SCBO-3.2 organoid line are likely to reflect changes in drug response of its parental tumor as a consequence of treatment.

The molecular profiles of the organoid lines can be useful for identification of potential combinatorial therapies!




SCBO-6 displayed an additive response to treatment with the FGFR inhibitor JNJ-42756493 and the mTOR inhibitor AZD8055, consistent with the presence of both an activating FGFR3 mutation and a nonsense mutation in TSC1.

Drug response observed in organoid culture can be recapitulated when assayed in an in vivo context!




Patient-derived organoids model treatment response of metastatic gastrointestinal cancers



Vlachogiannis et al. *Science*, 2018



Patient-derived organoids model treatment response of metastatic gastrointestinal cancers




Vlachogiannis et al. *Science*, 2018[illegible]

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

Vlachogiannis et al. *Science*, 2018



Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

Vlachogiannis et al. *Science*. 2018




Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

Vlachogiannis et al. *Science*. 2018





Evaluation of the cytotoxicity of drugs used in the treatment of IBD

GLUCOCORTICOIDS




Cytotoxic effect of methylprednisolone (MTPR) on 11 patient-derived organoids. Cells were exposed for 72 h to drug and cytotoxicity was evaluated by the Cell-titer Glo assay. The value is the percentage of treated cells vs untreated controls.

Relative expression (RE) of GILZ AND sgk1 after incubation for 72 h with MTPR. One-way ANOVA ($p = 0.004$) and Bonferroni post-test ** p value < 0.001 ; *** p value < 0.0001 . The data are reported as means \pm SE of three independent patient-derived organoids.




Evaluation of the cytotoxicity of drugs used in the treatment of IBD

THIOPURINES





Cytotoxic effect of azathioprine (AZA) on 11 patient-derived organoids. Cells were exposed for 72 h to drug and cytotoxicity was evaluated by the Cell-titer Glo assay. The value is the percentage of treated cells vs untreated controls.

Cytotoxic effect of mercaptopurine (MP) on 11 patient-derived organoids. Cells were exposed for 72 h to drug and cytotoxicity was evaluated by the Cell-titer Glo assay. The value is the percentage of treated cells vs untreated controls.




Organoids to study the effect of anti-inflammatory and immunomodulator drugs on epithelial barrier restoration

5-ASA
Azathioprine



The “MultiOrgan-on-a-Chip” Models



Picollet-D'hahan et al., Trends of Biotechnology 2021

Trends in Biotechnology

Schematic Representation of the Two Main Approaches for Developing Multi-OoC Systems:

(A) Through coupling of single OoC devices, each modeling a different organ, via capillary connection or a microfluidic motherboard (B); and (C) by integrating different organ models in a single plate, an approach that is more in line with the body-on-a-chip philosophy.